Objective — the study was aimed at assessing the clinical efficacy of treatment of complicated forms of psoriasis (erythroderma, arthropathy) in children administered with immunobiological agent adalimumab as a part of combination therapy. The efficacy was evaluated based on clinical index PASI (Psoriasis Area and Severity Index) and analysis of the average duration of remission. Short-term results of treatment of children were evaluated in 3 months. The aggregate data were indicative of stabilisation of psoriatic process. The results of general assessment of long-term results (in 1 year) were clearly indicative of persistent remission. The results of the study led to conclusion that adalimumab is highly effective for the treatment of erythrodermic psoriasis in children. The use of the standard dose of adalimumab provides quite rapid and clinically significant decrease in PASI, which is indicative of a positive impact on the severity and extent of erythrodermic psoriasis. This drug is safe for children provided that the standard screening procedures were carried out.